Trifunctional molecule and application thereof
US11535666B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 9, 2017 |
| Grant date | Dec 27, 2022 |
| Priority date | — |
| Expiry date | Aug 7, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure belongs to the field of biomedical technology, and particularly refers to a trifunctional molecule and the application thereof. The structure of the trifunctional molecule includes a first functional domain, a second functional domain and a third functional domain. These domains are capable of simultaneously binding to CD19, CD3, and T cell positive (negative) costimulatory factors, thereby producing the first and second signal required for T cell activation. The trifunctional molecule is a recombinant protein peptide chain, which can be produced by a eukaryotic cell expression system. The product has a single structure, simple purification process, high protein yield, and preparation process and product stability. The trifunctional molecule is superior to the anti-CD19/anti-CD3 BiTE bispecific antibody in killing CD19-positive target cells. Compared with the CAR-T technology targeting CD19, the trifunctional molecule is more convenient to use, the dose is controllable, and the side effects of CAR-T are avoided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.